Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
ID | Components | Size |
EP135-C01 | High-bind Plate | 1 plate |
EP135-C02 | Human CD30L | 15 μg |
EP135-C03 | Biotinylated Human CD30 | 10 μg |
EP135-C04 | Anti-CD30 Neutralizing Antibody | 20 μg |
EP135-C05 | Streptavidin-HRP | 10 μg |
EP135-C06 | Coating Buffer | 12 mL |
EP135-C07 | 10xWashing Buffer | 50 mL |
EP135-C08 | Blocking Buffer | 50 mL |
EP135-C09 | Substrate Solution | 12 mL |
EP135-C10 | Stop Solution | 7 mL |
2. Find the expiration date on the outside packaging and do not use reagents past their expiration date.
3. The opened kit should be stored per components table. The shelf life is 30 days from the date of opening.
INHIBITION OF CD30[Biotinylated]: CD30L BINDING BY ANTI-CD30 NEUTRALIZING ANTIBODY
Serial dilutions of Anti-CD30 Neutralizing antibody (Catalog # EP135-C04) (1:1 serial dilution, from 5 μg/mL to 0.019μg/mL) was added into Biotinylated CD30: CD30L binding reactions. The assay was performed according to the protocol described below. Background was subtracted from data points prior to log transformation and curve fitting (QC tested).
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides comprehensive tools for neuroscience research, including neuroscience proteins, pre-formed fibrils (PFFs), neural antibodies, neural factors, and more—aiming to accelerate disease modeling, drug screening, and neural mechanism studies.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Brentuximab vedotin | SGN-30; SGN-35; cAC-10; SGD-1010; cAC10-vcMMAE; cAC10-Val-Cit-MMAE | Approved | Millennium Pharmaceuticals Inc, Seagen Inc | Adcetris, 安适利 | United States | Hodgkin Disease; Lymphoma, Large-Cell, Anaplastic | Seagen Inc | 2011-08-19 | Lymphoma, Large-Cell, Anaplastic; Lymphoma, Primary Cutaneous Anaplastic Large Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lupus Erythematosus, Systemic; Sezary Syndrome; Lymphoma, T-Cell; Lymphoma; Leukemia, Myeloid, Acute; Lymphoma, T-Cell, Cutaneous; Leukemia, Mast-Cell; Scleroderma, Diffuse; Lymphoma, Non-Hodgkin; Hidradenitis Suppurativa; Mycosis Fungoides; Lymphomatoid Papulosis; Sarcoma, Kaposi; Neoplasms, Germ Cell and Embryonal; Graft vs Host Disease; Lymphoma, T-Cell, Peripheral; Solid tumours; Hematologic Neoplasms; HIV Infections; Lymphoma, B-Cell; Anemia, Refractory, with Excess of Blasts; Carcinoma; Hodgkin Disease; Hematologic Diseases; Mastocytosis, Systemic; Scleroderma, Systemic; Lymphoma, Large B-Cell, Diffuse; Enteropathy-Associated T-Cell Lymphoma; Neoplasms; Myelodysplastic Syndromes; Mesothelioma | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Acimtamig | AFM-13 | Phase 2 Clinical | The University Of Texas MD Anderson Cancer Center | Lymphoma, B-Cell; Lymphoma, T-Cell, Peripheral; Hodgkin Disease; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Mycosis Fungoides | Details |
ATLCAR.CD30 cells (UNC Lineberger Comprehensive Cancer Center) | Phase 2 Clinical | Unc Lineberger Comprehensive Cancer Center | Lymphoma, T-Cell, Peripheral; Lymphatic Diseases; Immunoproliferative Disorders; Neoplasms; Hodgkin Disease; Immune System Diseases; Lymphoproliferative Disorders; Lymphoma; Lymphoma, Non-Hodgkin; Neoplasms, Germ Cell and Embryonal | Details | |
Autologous CD30+ CAR T Cells therapy(New York Medical College) | Phase 2 Clinical | New York Medical College, University Of North Carolina At Chapel Hill | Hodgkin Disease | Details | |
Itezocabtagene autoleucel | TT-11; TT11 | Phase 2 Clinical | Tessa Therapeutics Ltd | Lymphoma, B-Cell; Lymphoma, T-Cell, Peripheral; Lymphoma, Large B-Cell, Diffuse; Hodgkin Disease; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Large-Cell, Anaplastic | Details |
BRD-01 | BRD-01 | Phase 2 Clinical | Wuhan BioRaid Biotechnology Co Ltd | Hematologic Neoplasms; Hodgkin Disease | Details |
GEN3017 | GEN-3017 | Phase 2 Clinical | Genmab A/S | Hematologic Neoplasms; Hodgkin Disease; Lymphoma, Non-Hodgkin | Details |
CD30 biAb-AATC(The Medical College Of Wisconsin Nonprofit) | Phase 2 Clinical | The Medical College Of Wisconsin Nonprofit | Lymphoma, B-Cell; Leukemia; Hodgkin Disease; Lymphoma, Large-Cell, Anaplastic; Lymphoma; Lymphoma, T-Cell, Cutaneous | Details | |
HSP-CAR-30 | HSP-CAR-30 | Phase 2 Clinical | Fundació Institut De Recerca De L | Hodgkin Disease; Lymphoma, T-Cell | Details |
Anti-CD30 CAR T-cell therapy (General Hospital of the People's Liberation Army/Cellular Biomedicine) | CAR30-NKT; CBM-C30.1; CD30ScFv-CD8-CD137-CD3zeta | Phase 2 Clinical | Pla General Hospital | Hodgkin Disease | Details |
Anti-CD30 chimeric antigen receptor T cell therapy (Immune cell) | Phase 1 Clinical | Immune Cell Inc | Hodgkin Disease; Lymphoma, Large-Cell, Anaplastic | Details | |
CD30.CAR-EBVST cell therapy (Baylor College of Medicine) | TT-11X | Phase 1 Clinical | Baylor College Of Medicine, Tessa Therapeutics Ltd | Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Extranodal NK-T-Cell | Details |
EBV-specific-CAR.CD30 | EBV-specific-CAR.CD30; CAR.CD30 EBV-specific-CTLs | Phase 1 Clinical | Baylor College Of Medicine, Texas Children'S Hospital, Methodist Hospital System | Hodgkin Disease; Lymphoma, Non-Hodgkin | Details |
Anti-CD30 CAR T-cell therapy (Wuhan Bio-Raid) | Phase 1 Clinical | Wuhan BioRaid Biotechnology Co Ltd | Lymphoma, T-Cell, Peripheral; Hematologic Neoplasms; Leukemia-Lymphoma, Adult T-Cell; Hodgkin Disease; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Large-Cell, Anaplastic; Angioimmunoblastic T-cell Lymphoma | Details | |
Recombinant chimeric anti-CD30 monoclonal antibody-MCC-DM1 | F0002-ADC; B-006(SCP) | Phase 1 Clinical | Shanghai Crosslink Pharmaceutical R & D Co Ltd, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd | Hematologic Neoplasms; Lymphoma, T-Cell, Peripheral; Hodgkin Disease; Lymphoma, Large-Cell, Anaplastic | Details |
CD30.CAR | H-27721; CD30.CAR | Phase 1 Clinical | Baylor College Of Medicine | Lymphoma, B-Cell; Lymphoma, T-Cell, Peripheral; Hodgkin Disease; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin | Details |
Anti-CD20/CD30-CAR-T Cell therapy(Shanghai Tongji Hospital) | Phase 1 Clinical | Shanghai Tongji Hospital | Lymphoma, B-Cell; Leukemia, B-Cell; Lymphoma | Details | |
CD30-Targeted LCAR-HL30 Cells therapy(Legend Biotechnology) | Phase 1 Clinical | Nanjing Legend Biotechnology Co Ltd | Hodgkin Disease; Lymphoma, Large-Cell, Anaplastic | Details | |
SGN-35C | SGN-35C | Phase 1 Clinical | Seagen Inc | Lymphoma, T-Cell, Peripheral; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Lymphoma; Lymphoma, Large-Cell, Anaplastic | Details |
SGN-35T | SGN-35T; SGN-CD30C; PF-08046045 | Phase 1 Clinical | Seagen Inc | Solid tumours; Lymphoma, T-Cell, Peripheral; Lymphoma, Large B-Cell, Diffuse; Hodgkin Disease; Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma, Large-Cell, Anaplastic; Lymphoma, T-Cell, Cutaneous | Details |
Anti-CD30 CAR T-cell therapy | Phase 1 Clinical | Minghui (Nanjing) Gene Biotechnology Co Ltd | Hodgkin Disease; Lymphoma, Large-Cell, Anaplastic | Details | |
Anti-CD30 CAR-T cell therapy (National Cancer Institute) | Hu30-CD28z | Phase 1 Clinical | National Cancer Institute | Lymphoma, T-Cell, Peripheral; Enteropathy-Associated T-Cell Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Large-Cell, Anaplastic; Lymphoma | Details |
PRA-052 | PRA-052 | Phase 1 Clinical | Prometheus Biosciences Inc | Colitis, Ulcerative | Details |
SGN-CD30C | SGN-CD30C | Phase 1 Clinical | Seattle Genetics Inc | Lymphoma | Details |
Anti-CD30 chimeric antigen receptor T cell therapy (Yake Biotechnology) | Clinical | Shanghai YaKe Biotechnology Co Ltd | Hodgkin Disease | Details |
This web search service is supported by Google Inc.